Anthony S. Marucci - 05 Aug 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
President & CEO, Director
Signature
/s/ Samuel B. Martin, attorney in fact for Anthony S. Marucci
Issuer symbol
CLDX
Transactions as of
05 Aug 2021
Net transactions value
+$148,554
Form type
4
Filing time
09 Aug 2021, 07:21:16 UTC
Previous filing
21 Jun 2021
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $148,554 +3,537 +15% $42.00 27,231 05 Aug 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -3,537 -100% $0.000000* 0 05 Aug 2021 Common Stock 3,537 $42.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,256 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Option Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021.
F3 As of August 5, 2015, the option is fully vested.